Sumitomo Mitsui Trust Group Inc. Decreases Stock Position in Avantor, Inc. (NYSE:AVTR)

Sumitomo Mitsui Trust Group Inc. lowered its position in shares of Avantor, Inc. (NYSE:AVTR - Free Report) by 1.7% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,498,903 shares of the company's stock after selling 26,687 shares during the quarter. Sumitomo Mitsui Trust Group Inc. owned 0.22% of Avantor worth $31,582,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. MassMutual Private Wealth & Trust FSB grew its stake in Avantor by 99.5% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,253 shares of the company's stock valued at $26,000 after acquiring an additional 625 shares during the last quarter. UMB Bank n.a. acquired a new stake in Avantor in the 3rd quarter valued at about $49,000. Nisa Investment Advisors LLC grew its stake in Avantor by 69.6% in the 3rd quarter. Nisa Investment Advisors LLC now owns 2,035 shares of the company's stock valued at $53,000 after acquiring an additional 835 shares during the last quarter. GAMMA Investing LLC grew its stake in Avantor by 89.9% in the 3rd quarter. GAMMA Investing LLC now owns 2,715 shares of the company's stock valued at $70,000 after acquiring an additional 1,285 shares during the last quarter. Finally, Livforsakringsbolaget Skandia Omsesidigt grew its stake in Avantor by 278.0% in the 3rd quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 5,031 shares of the company's stock valued at $130,000 after acquiring an additional 3,700 shares during the last quarter. Hedge funds and other institutional investors own 95.08% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. Stifel Nicolaus decreased their price target on shares of Avantor from $28.00 to $26.00 and set a "buy" rating on the stock in a research note on Monday, February 10th. Morgan Stanley decreased their target price on shares of Avantor from $27.00 to $25.00 and set an "overweight" rating on the stock in a research report on Monday, February 10th. Royal Bank of Canada cut their price target on shares of Avantor from $33.00 to $31.00 and set an "outperform" rating on the stock in a report on Monday, February 10th. Barclays cut their price target on shares of Avantor from $26.00 to $23.00 and set an "overweight" rating on the stock in a report on Monday, February 10th. Finally, Robert W. Baird dropped their price objective on shares of Avantor from $27.00 to $26.00 and set an "outperform" rating on the stock in a research note on Monday, October 28th. Three analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Avantor has an average rating of "Moderate Buy" and a consensus target price of $26.15.

Avantor Price Performance

NYSE:AVTR traded down $0.24 during trading hours on Friday, reaching $17.87. The company had a trading volume of 3,913,664 shares, compared to its average volume of 5,012,515. The stock has a 50-day moving average of $21.44 and a two-hundred day moving average of $23.26. Avantor, Inc. has a one year low of $17.83 and a one year high of $28.00. The firm has a market capitalization of $12.16 billion, a PE ratio of 38.84, a PEG ratio of 3.87 and a beta of 1.28. The company has a quick ratio of 1.06, a current ratio of 1.54 and a debt-to-equity ratio of 0.84.

Avantor (NYSE:AVTR - Get Free Report) last posted its quarterly earnings results on Wednesday, February 12th. The company reported $0.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.26 by $0.01. Avantor had a return on equity of 12.24% and a net margin of 4.54%. During the same period in the previous year, the business earned $0.22 EPS. Analysts forecast that Avantor, Inc. will post 0.98 earnings per share for the current year.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.